The PI3K/AKT Pathway as a Target for Cancer Treatment

被引：636
|
作者：
Mayer, Ingrid A. [1 ,2 ,3 ]
Arteaga, Carlos L. [1 ,2 ,3 ]
机构：
[1] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA
[3] Vanderbilt Univ, Sch Med, Breast Canc Program, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA
来源：
ANNUAL REVIEW OF MEDICINE, VOL 67 | 2016年 / 67卷
关键词：
phosphoinositide 3-kinase (PI3K)/AKT; mammalian target of rapamycin (mTOR); pathway inhibitors; breast cancer; lymphoproliferative disorders; mutation; CHRONIC LYMPHOCYTIC-LEUKEMIA; POSITIVE BREAST-CANCER; RENAL-CELL CARCINOMA; PIK3CA MUTATIONS; PHOSPHOINOSITIDE; 3-KINASE; PHOSPHATIDYLINOSITOL; ESTROGEN DEPRIVATION; TYROSINE KINASE; MAMMARY-TUMORS; UP-REGULATION;
D O I：
10.1146/annurev-med-062913-051343
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Anticancer targeted therapies are designed to exploit a particular vulnerability in the tumor, which in most cases results from its dependence on an oncogene and/or loss of a tumor suppressor. Genes in the phosphoinositide 3-kinase (PI3K)/AKT pathway are the most frequently altered in human cancers. Aberrant activation of this pathway, as a result of these somatic alterations, is associated with cellular transformation, tumorigenesis, cancer progression, and drug resistance. Several drugs targeting PI3K/ATK are currently in clinical trials, alone or in combination, in both solid tumors and hematologic malignancies. These drugs are the focus of this review.
引用
收藏
页码：11 / 28
页数：18
相关论文
共 50 条
  • [1] PI3K/AKT signaling pathway and cancer: an updated review
    Martini, Miriam
    De Santis, Maria Chiara
    Braccini, Laura
    Gulluni, Federico
    Hirsch, Emilio
    ANNALS OF MEDICINE, 2014, 46 (06) : 372 - 383
  • [2] PI3K and AKT: Unfaithful Partners in Cancer
    Faes, Seraina
    Dormond, Olivier
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2015, 16 (09): : 21138 - 21152
  • [3] The PI3K/AKT/mTOR Pathway as a Therapeutic Target in Endometrial Cancer
    Slomovitz, Brian M.
    Coleman, Robert L.
    CLINICAL CANCER RESEARCH, 2012, 18 (21) : 5856 - 5864
  • [4] Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer
    Li, Huayi
    Prever, Lorenzo
    Hirsch, Emilio
    Gulluni, Federico
    CANCERS, 2021, 13 (14)
  • [5] The PI3K Pathway As Drug Target in Human Cancer
    Courtney, Kevin D.
    Corcoran, Ryan B.
    Engelman, Jeffrey A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (06) : 1075 - 1083
  • [6] PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer
    Li, HaiXia
    Zeng, JianFang
    Shen, Keng
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2014, 290 (06) : 1067 - 1078
  • [7] The PI3K/AKT Pathway and Renal Cell Carcinoma
    Guo, Huifang
    German, Peter
    Bai, Shanshan
    Barnes, Sean
    Guo, Wei
    Qi, Xiangjie
    Lou, Hongxiang
    Liang, Jiyong
    Jonasch, Eric
    Mills, Gordon B.
    Ding, Zhiyong
    JOURNAL OF GENETICS AND GENOMICS, 2015, 42 (07) : 343 - 353
  • [8] Targeting the PI3K/Akt/mTOR Pathway for Breast Cancer Therapy
    Cidado, Justin
    Park, Ben Ho
    JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 2012, 17 (3-4) : 205 - 216
  • [9] PI3K/Akt Pathway: A Potential Therapeutic Target for Chronic Pain
    Chen, Shu-Ping
    Zhou, Ya-Qun
    Liu, Dai-Qiang
    Zhang, Wen
    Manyande, Anne
    Guan, Xue-Hai
    Tian, Yu-Ke
    Ye, Da-Wei
    Omar, Deeq Mohamed
    CURRENT PHARMACEUTICAL DESIGN, 2017, 23 (12) : 1860 - 1868
  • [10] The PI3K/Akt pathway: a target for curcumin's therapeutic effects
    Aliyari, Mahdieh
    Ghoflchi, Sahar
    Hashemy, Seyed Isaac
    Hashemi, Seyedeh Fatemeh
    Reihani, Amirali
    Hosseini, Hossein
    JOURNAL OF DIABETES AND METABOLIC DISORDERS, 2025, 24 (01)
12345